[New prospective therapy for @entity1067 with XXXX ].

@entity1 @entity251 @entity586 @entity585 @entity1067 @entity1486
A randomized, double blind, placebo-controlled study (placebo and @entity585 1 or 5 mg/die) was carried out in 34 @entity1 with @entity1067 ( @entity1067 ). After 12 months of treatment all @entity1 received @entity585 5 mg/die. Follow-up ranges from 18 to 36 months. One year after treatment, @entity1 receiving @entity585 1 or 5 mg/die, showed significant decrease (one-way ANOVA) of serum @entity586 (-70.1% and -69.6%, respectively), serum @entity1486 (-50% and -50.8%, respectively) and prostate volume (-36.3% and -31.8%, respectively). Comparable modifications of such parameters were observed in the placebo group only during the second year of the study when they were shifted to @entity585 treatment (5 mg/die). No increase of serum @entity251 was observed in any group. Maximum urinary flow rate increased on the average, after one year, by 2.6 and 3.6 ml/s in @entity1 receiving @entity585 1 and 5 mg/die, respectively; a 1.3 ml/s increase occurred in the placebo group. The total urinary symptom score (Boyarsky) decreased in all three @entity1 groups. Results of this study show that a few months are necessary to exert a significant therapeutic effect. The drug is well tolerated and does not decrease the @entity1 's sexual activity. @entity585 certainly opens new perspectives in the treatment of @entity1067 .
